Literature DB >> 20444416

The stunned beta cell: a brief history.

Ele Ferrannini1.   

Abstract

beta cell dysfunction is sufficient to cause hyperglycemia; beta cell loss is not necessary but, if severe, can be sufficient and may be accompanied by intrinsic beta cell dysfunction. Clinical testing can differentiate beta cell capacity from beta cell glucose sensitivity but cannot ascribe either to relative changes in beta cell mass versus function. However, longitudinal and intervention studies indicate that beta cell glucose insensitivity (stunning) closely tracks with hyperglycemia and is, at least in part, reversible. Rescuing stunned beta cells is a key therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20444416     DOI: 10.1016/j.cmet.2010.04.009

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  80 in total

1.  The battered β-cell: usual suspects and guilt by association.

Authors:  R Paul Robertson
Journal:  J Clin Endocrinol Metab       Date:  2011-12       Impact factor: 5.958

2.  Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews
Journal:  Diabetologia       Date:  2012-04-20       Impact factor: 10.122

Review 3.  The past 10 years-new hormones, new functions, new endocrine organs.

Authors:  Roger Bouillon; Daniel J Drucker; Ele Ferrannini; Steven Grinspoon; Clifford J Rosen; Paul Zimmet
Journal:  Nat Rev Endocrinol       Date:  2015-09-01       Impact factor: 43.330

4.  50 years forward: beta cells.

Authors:  Philippe A Halban
Journal:  Diabetologia       Date:  2015-05-10       Impact factor: 10.122

Review 5.  Hepatic Insulin Clearance: Mechanism and Physiology.

Authors:  Sonia M Najjar; Germán Perdomo
Journal:  Physiology (Bethesda)       Date:  2019-05-01

Review 6.  SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

Authors:  Ele Ferrannini; Anna Solini
Journal:  Nat Rev Endocrinol       Date:  2012-02-07       Impact factor: 43.330

7.  Inactivation of specific β cell transcription factors in type 2 diabetes.

Authors:  Shuangli Guo; Chunhua Dai; Min Guo; Brandon Taylor; Jamie S Harmon; Maike Sander; R Paul Robertson; Alvin C Powers; Roland Stein
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

Review 8.  Perioperative Management of Hyperglycemia and Diabetes in Cardiac Surgery Patients.

Authors:  Rodolfo J Galindo; Maya Fayfman; Guillermo E Umpierrez
Journal:  Endocrinol Metab Clin North Am       Date:  2018-03       Impact factor: 4.741

Review 9.  Targeting the pancreatic β-cell to treat diabetes.

Authors:  Amedeo Vetere; Amit Choudhary; Sean M Burns; Bridget K Wagner
Journal:  Nat Rev Drug Discov       Date:  2014-02-14       Impact factor: 84.694

Review 10.  Anti-diabetic medications: How to make a choice?

Authors:  Amir Babiker; Mohammed Al Dubayee
Journal:  Sudan J Paediatr       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.